Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.
2.

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.

Amanzada A, Goralczyk A, Moriconi F, Blaschke M, Schaefer IM, van Thiel D, Mihm S, Ramadori G.

Dig Dis Sci. 2011 Nov;56(11):3296-304. doi: 10.1007/s10620-011-1933-2. Epub 2011 Oct 13.

PMID:
21994136
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
4.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

PMID:
16904047
[PubMed - indexed for MEDLINE]
Free Article
5.

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.

Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group.

Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130.

PMID:
19676125
[PubMed - indexed for MEDLINE]
6.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
[PubMed - indexed for MEDLINE]
7.

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.

Kogure T, Ueno Y, Fukushima K, Nagasaki F, Kondo Y, Inoue J, Matsuda Y, Kakazu E, Yamamoto T, Onodera H, Miyazaki Y, Okamoto H, Akahane T, Kobayashi T, Mano Y, Iwasaki T, Ishii M, Shimosegawa T.

World J Gastroenterol. 2008 Dec 21;14(47):7225-4230.

PMID:
19084938
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M.

J Gastroenterol. 2010 Jun;45(6):656-65. doi: 10.1007/s00535-009-0195-7. Epub 2010 Jan 30.

PMID:
20112032
[PubMed - indexed for MEDLINE]
9.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
[PubMed - indexed for MEDLINE]
10.

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V.

Cent Eur J Public Health. 2012 Jun;20(2):150-5.

PMID:
22966742
[PubMed - indexed for MEDLINE]
11.

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.

Aziz H, Raza A, Waheed Y, Gill U, Gill ML.

Int J Infect Dis. 2012 Aug;16(8):e597-602. doi: 10.1016/j.ijid.2012.03.012. Epub 2012 Jun 1.

PMID:
22658873
[PubMed - indexed for MEDLINE]
Free Article
12.

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.

Aliment Pharmacol Ther. 2013 Jan;37(1):81-90. doi: 10.1111/apt.12112. Epub 2012 Nov 5.

PMID:
23121150
[PubMed - indexed for MEDLINE]
13.

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.

Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

PMID:
19139619
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.

Piccinino F, Felaco FM, Sagnelli E, Aprea L, Messina V, Pasquale G, Filippini P, Scolastico C.

Res Virol. 1998 Sep-Oct;149(5):283-91.

PMID:
9879606
[PubMed - indexed for MEDLINE]
15.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
[PubMed - indexed for MEDLINE]
16.

Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.

Ueda Y, Marusawa H, Kaido T, Ogura Y, Oike F, Mori A, Ogawa K, Yoshizawa A, Hatano E, Miyagawa-Hayashino A, Haga H, Egawa H, Takada Y, Uemoto S, Chiba T.

J Viral Hepat. 2012 Jan;19(1):32-8. doi: 10.1111/j.1365-2893.2010.01398.x. Epub 2010 Dec 3.

PMID:
21129128
[PubMed - indexed for MEDLINE]
17.

Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.

Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans BL, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HL.

Antivir Ther. 2012;17(3):509-17. doi: 10.3851/IMP2016. Epub 2011 Dec 13.

PMID:
22300892
[PubMed - indexed for MEDLINE]
18.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
19.

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.

PMID:
21745312
[PubMed - indexed for MEDLINE]
20.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk